Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Meijer, Tineke W H ^a   Bussink, Johan ^a   Zatovicova, Miriam ^b   Span, Paul N ^a   Lok, Jasper ^a   Supuran, Claudiu T ^c   Kaanders, Johannes H A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF VIROLOGY   (Slovakia)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3'(3'',5'' DIMETHYLPHENYL) UREIDO]PHENYL SULFAMATE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; GELATINASE B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; UNCLASSIFIED DRUG; CARBONATE DEHYDRATASE IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL METABOLISM; CELL PROLIFERATION; CHOP GENE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LARYNX SQUAMOUS CELL CARCINOMA; MMP9 GENE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LARYNGEAL NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASE IV; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARYNGEAL NEOPLASMS; MICE; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907149054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108068     Document Type: Article

References (37)

1. Meijer TW, Kaanders JH, Span PN, Bussink J (2012) Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18: 5585-5594.
2. Chiche J, Ilc K, Brahimi-Horn MC, Pouyssegur J (2010) Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv Enzyme Regul 50: 20-33.
3. Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10: 767-777.
4. Otero-Rey EM, Somoza-Martin M, Barros-Angueira F, Garcia-Garcia A (2008) Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol 44: 193-199.
5. Cianchi F, Vinci MC, Supuran CT, Peruzzi B, De Giuli P, et al. (2010) Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 334: 710-719.
6. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl 2: 24S-42S.
7. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, et al. (2009) Hypoxiainducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358-368.
8. Pastorekova S, Zatovicova M, Pastorek J (2008) Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 14: 685-698.
9. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7: 168-181.
10. Hoogsteen IJ, Marres HA, Wijffels KI, Rijken PF, Peters JP, et al. (2005) Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11: 97-106.
11. Ilie MI, Hofman V, Ortholan C, Ammadi RE, Bonnetaud C, et al. (2011) Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer 128: 1614-1623.
12. Chien MH, Ying TH, Hsieh YH, Lin CH, Shih CH, et al. (2012) Tumorassociated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol 48: 417-423.
13. De Simone G, Alterio V, Supuran CT (2013) Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 8: 793-810.
14. Winum JY, Carta F, Ward C, Mullen P, Harrison D, et al. (2012) Ureidosubstituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorg Med Chem Lett 22: 4681-4685.
15. Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, et al. (2012) Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 55: 5591-5600.
16. Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, et al. (2006) Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat Res 165: 326-336.
17. Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, et al. (2005) Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76: 194-199.
18. van Laarhoven HW, Bussink J, Lok J, Punt CJ, Heerschap A, et al. (2004) Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. Int J Radiat Oncol Biol Phys 60: 310-321.
19. Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, et al. (2012) Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer 12: 463.
20. Stegeman H, Kaanders JH, van der Kogel AJ, Iida M, Wheeler DL, et al. (2013) Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol 106: 383-389.
21. Putney LK, Barber DL (2004) Expression profile of genes regulated by activity of the Na-H exchanger NHE1. BMC Genomics 5: 46.
22. Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, et al. (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 93: 1267-1276.
23. Zat'ovicova M, Tarabkova K, Svastova E, Gibadulinova A, Mucha V, et al. (2003) Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 282: 117-134.
24. Westbury CB, Pearson A, Nerurkar A, Reis-Filho JS, Steele D, et al. (2007) Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. Br J Radiol 80: 934-938.
25. McDonald PC, Winum JY, Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3: 84-97.
26. Zatovicova M, Pastorekova S (2013) Modulation of cell surface density of carbonic anhydrase IX by shedding of the ectodomain and endocytosis. Acta Virol 57: 257-264.
27. Ahlskog JK, Dumelin CE, Trussel S, Marlind J, Neri D (2009) In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 19: 4851-4856.
28. Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, et al. (2011) Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 99: 424-431.
29. Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, et al. (2013) Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiother Oncol.
30. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, et al. (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71: 3364-3376.
31. Pacchiano F, Carta F, McDonald PC, Lou Y, Vullo D, et al. (2011) Ureidosubstituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 54: 1896-1902.
32. Touisni N, Maresca A, McDonald PC, Lou Y, Scozzafava A, et al. (2011) Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 54: 8271-8277.
33. Gieling RG, Parker CA, De Costa LA, Robertson N, Harris AL, et al. (2013) Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem 28: 360-369.
34. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, et al. (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90: 985-990.
35. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, et al. (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29: 121-126.
36. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, et al. (2010) The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 120: 127-141.
37. Xu K, Mao X, Mehta M, Cui J, Zhang C, et al. (2013) Elucidation of How Cancer Cells Avoid Acidosis through Comparative Transcriptomic Data Analysis. PLoS One 8: e71177.